Search

Your search keyword '"Tsai, C-M."' showing total 191 results
Start Over Author "Tsai, C-M." Search Limiters Available in Library Collection
191 results on '"Tsai, C-M."'

2. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Author

Della-Fiorentina, S., Begbie, S., Jennens, R., Dass, J., Pittman, K., Ivanova, N., Koynova, T., Petrov, P., Tomova, A., Tzekova, V., Couture, F., Hirsh, V., Burkes, R., Sangha, R., Ambrus, M., Janaskova, T., Musil, J., Novotny, J., Zatloukal, P., Jakesova, J., Klenha, K., Roubec, J., Vanasek, J., Fayette, J., Barlesi, F., Bennouna-Louridi, J., Chouaid, C., Mazières, J., Vallerand, H., Robinet, G., Souquet, P.-J., Spaeth, D., Schott, R., Lena, H., Martinet, Y., El Kouri, C., Baize, N., Scherpereel, A., Molinier, O., Fuchs, F., Josten, K.M., Manegold, C., Marschner, N., Schneller, F., Overbeck, T., Thomas, M., von Pawel, J., Reck, M., Schuette, W., Hagen, V., Schneider, C.-P., Georgoulias, V., Varthalitis, I., Zarogoulidis, K., Syrigos, K., Papandreou, C., Bocskei, C., Csanky, E., Juhasz, E., Losonczy, G., Mark, Z., Molnar, I., Papai-Szekely, Z., Tehenes, S., Vinkler, I., Almel, S., Bakshi, A., Bondarde, S., Maru, A., Pathak, A., Pedapenki, R.M., Prasad, K., Prasad, S.V.S.S., Kilara, N., Gorijavolu, D., Deshmukh, C.D., John, S., Sharma, L.M., Amoroso, D., Bajetta, E., Bidoli, P., Bonetti, A., De Marinis, F., Maio, M., Passalacqua, R., Cascinu, S., Bearz, A., Bitina, M., Brize, A., Purkalne, G., Skrodele, M., Baba, A.A., Ratnavelu, K., Saw, M.H., Samson-Fernando, M.C., Ladrera, G.E., Jassem, J., Koralewski, P., Serwatowski, P., Krzakowski, M., Cebotaru, C., Filip, D., Ganea-Motan, D.E., Ianuli, C.H., Manolescu, I.G., Udrea, A., Burdaeva, O., Byakhov, M., Filippov, A., Lazarev, S., Mosin, I., Orlov, S., Udovitsa, D., Khorinko, A., Protsenko, S., Chang, A., Lim, H.L., Tan, Y.O., Tan, E.H., Bastus Piulats, R., Garcia-Foncillas, J., Valdivia, J., de Castro, J., Domine Gomez, M., Kim, S.W., Lee, J.-S., Kim, H.K., Lee, J.S., Shin, S.W., Kim, D.-W., Kim, Y.-C., Park, K.C., Chang, C.-S., Chang, G.-C., Goan, Y.-G., Su, W.-C., Tsai, C.-M., Kuo, H.-P., Benekli, M., Demir, G., Gokmen, E., Sevinc, A., Crawford, J., Giaccone, G., Haigentz, M., Owonikoko, T., Agarwal, M., Pandit, S., Araujo, R., Vrindavanam, N., Bonomi, P., Berg, A., Wade, J., Bloom, R., Amin, B., Camidge, R., Hill, D., Rarick, M., Flynn, P., Klein, L., Lo Russo, K., Neubauer, M., Richards, P., Ruxer, R., Savin, M., Weckstein, D., Rosenberg, R., Whittaker, T., Richards, D., Berry, W., Ottensmeier, C., Dangoor, A., Steele, N., Summers, Y., Rankin, E., Rowley, K., Giridharan, S., Kristeleit, H., Humber, C., Taylor, P., Ramalingam, S., Perez-Soler, R., Douillard, J.-Y., Thatcher, N., Wang, Y., Pultar, P., Zhu, J., and Malik, R.

Published
2013
Full Text
View/download PDF

3. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Author

Yoshioka, H., Azuma, K., Yamamoto, N., Takahashi, T., Nishio, M., Katakami, N., Ahn, M. J., Hirashima, T., Maemondo, M., Kim, S. W., Kurosaki, M., Akinaga, S., Park, K., Tsai, C. M., Tamura, T., Mitsudomi, T., and Nakagawa, K.

Published
2015
Full Text
View/download PDF

19. Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)

Author

Felip, E., primary, Nishio, M., additional, Orlov, S., additional, Park, K., additional, Yu, C.-J., additional, Tsai, C.-M., additional, Cobo, M., additional, McKeage, M., additional, Su, W.-C., additional, SK Mok, T., additional, Scagliotti, G.V., additional, Spigel, D., additional, Passos, V.Q., additional, Chen, Z., additional, and Shaw, A.T., additional

Published
2018
Full Text
View/download PDF

22. Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)

Author

Cappuzzo, F., primary, Soo, R., additional, Hochmair, M., additional, Schuler, M., additional, Mok, T.S.K., additional, Stehle, G., additional, Cseh, A., additional, Lorence, R.M., additional, Linden, S., additional, Forman, N.D., additional, and Tsai, C.-M., additional

Published
2016
Full Text
View/download PDF

23. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)

Author

Felip, E., primary, Orlov, S., additional, Park, K., additional, Yu, C.-J., additional, Tsai, C.-M., additional, Nishio, M., additional, Dols, M.C., additional, McKeage, M., additional, Su, W.-C., additional, Mok, T.S.K., additional, Scagliotti, G., additional, Spigel, D.R., additional, Passos, V.Q., additional, Chen, V., additional, Munarini, F., additional, and Shaw, A., additional

Published
2016
Full Text
View/download PDF

24. Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC) : RADIANT trial

Author

O'Brien, MER, Eberhardt, Wilfried, Altorki, N. K., Spigel, D. R., Crino, L., Tsai, C. M., Cho, E. K., Kim, J. H., Szczesna, A., Hoffman, P. C., Burghuber, O., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Park, J. W., Shepherd, F. A., Kelly, K., and Tarceva Radiant Investigator Grp

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Treatment duration, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), medicine.disease, Placebo, respiratory tract diseases, Surgery, Oncology, medicine, In patient, Erlotinib, business, Adjuvant, medicine.drug
Abstract

7535 Background: We describe treatment duration and safety in the safety full analysis set (sFAS) and in the subset of pts with EGFR del19 and L858R mutations (EGFR M+). Methods: RADIANT was a rand...

Published
2014

25. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC) : RADIANT results

Author

Kelly, K., Altorki, N. K., Eberhardt, Wilfried, O'Brien, MER, Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Park, J. W., Shepherd, F. A., and Tarceva Radiant Investigator Grp

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), medicine.disease, Placebo, Surgery, Internal medicine, medicine, Clinical endpoint, Immunohistochemistry, Adenocarcinoma, Erlotinib, Stage (cooking), business, Adjuvant, medicine.drug
Abstract

7501 Background: The proven efficacy of E in advanced NSCLC warranted its evaluation in the adjuvant setting. BR.21 data suggested pts with EGFR positive tumors (IHC/FISH) were more likely to benefit from E. Methods: Completely resected IB-IIIA NSCLC pts were randomized 2:1 to receive E 150 mg qd or P for 2 years. Pts were stratified according to stage, histology, prior adjuvant chemotherapy, smoking status, EGFR FISH status, and country. The primary endpoint was disease free survival (DFS) in the full analysis set (FAS). Secondary endpoints included overall survival (OS) in the FAS and DFS and OS in the EGFR mutation (EGFR M+) subset (del19/L858R). Hierarchical testing procedure was used. Results: Between NOV 2007 and JUL 2010, 973 pts were randomized. Baseline characteristics were balanced between arms (age > 65 41%; female 41%; stage IB 51%, II 33%, IIIA 16% [AJCC 6th ed]; adenocarcinoma 59%; prior adjuvant chemotherapy 53%; never smoker 20%; Asian 17%; EGFR FISH+ 72% and EGFR M+ 16.5%). The planned nu...

Published
2014

26. Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial

Author

Shepherd, F. A., Altorki, N. K., Eberhardt, Wilfried, O'Brien, Mary, Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Richardson, F. C., Kelly, K., and Tarceva Radiant Investigator Grp

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), macromolecular substances, Placebo, medicine.disease, respiratory tract diseases, carbohydrates (lipids), stomatognathic diseases, Exon, Egfr tki, Internal medicine, Immunology, otorhinolaryngologic diseases, medicine, Erlotinib, business, Adjuvant, medicine.drug
Abstract

7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts with tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to EGFR TKIs. Methods: RADIA...

Published
2014

30. EGFR Mutation Testing Practices within the Asia Pacific Region Results of a Multicenter Diagnostic Survey

Author

Yatabe, Y, Kerr, KM, Utomo, A, Rajadurai, P, Van, KT, Du, X, Chou, T-Y, Enriquez, MLD, Lee, GK, Iqbal, J, Shuangshoti, S, Chung, J-H, Hagiwara, K, Liang, Z, Normanno, N, Park, K, Toyooka, S, Tsai, C-M, Waring, P, Zhang, L, McCormack, R, Ratcliffe, M, Itoh, Y, Sugeno, M, Mok, T, Yatabe, Y, Kerr, KM, Utomo, A, Rajadurai, P, Van, KT, Du, X, Chou, T-Y, Enriquez, MLD, Lee, GK, Iqbal, J, Shuangshoti, S, Chung, J-H, Hagiwara, K, Liang, Z, Normanno, N, Park, K, Toyooka, S, Tsai, C-M, Waring, P, Zhang, L, McCormack, R, Ratcliffe, M, Itoh, Y, Sugeno, M, and Mok, T

Abstract

INTRODUCTION: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. METHODS: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. RESULTS: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. CONCLUSIONS: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.

Published
2015

31. 446P Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

Author

Wu, Y.-L., primary, Sequist, L.V., additional, Geater, S.L., additional, Orlov, S., additional, Lee, K.H., additional, Tsai, C.-M., additional, Kato, T., additional, Kiura, K., additional, Barrios, C.H., additional, Schuler, M., additional, Hirsh, V., additional, Yamamoto, N., additional, O'Byrne, K., additional, Mok, T., additional, Massey, D., additional, Märten, A., additional, and Yang, J.C.-H., additional

Published
2015
Full Text
View/download PDF

38. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Author

Ramalingam, S., primary, Crawford, J., additional, Chang, A., additional, Manegold, C., additional, Perez-Soler, R., additional, Douillard, J.-Y., additional, Thatcher, N., additional, Barlesi, F., additional, Owonikoko, T., additional, Wang, Y., additional, Pultar, P., additional, Zhu, J., additional, Malik, R., additional, Giaccone, G., additional, Della-Fiorentina, S., additional, Begbie, S., additional, Jennens, R., additional, Dass, J., additional, Pittman, K., additional, Ivanova, N., additional, Koynova, T., additional, Petrov, P., additional, Tomova, A., additional, Tzekova, V., additional, Couture, F., additional, Hirsh, V., additional, Burkes, R., additional, Sangha, R., additional, Ambrus, M., additional, Janaskova, T., additional, Musil, J., additional, Novotny, J., additional, Zatloukal, P., additional, Jakesova, J., additional, Klenha, K., additional, Roubec, J., additional, Vanasek, J., additional, Fayette, J., additional, Bennouna-Louridi, J., additional, Chouaid, C., additional, Mazières, J., additional, Vallerand, H., additional, Robinet, G., additional, Souquet, P.-J., additional, Spaeth, D., additional, Schott, R., additional, Lena, H., additional, Martinet, Y., additional, El Kouri, C., additional, Baize, N., additional, Scherpereel, A., additional, Molinier, O., additional, Fuchs, F., additional, Josten, K.M., additional, Marschner, N., additional, Schneller, F., additional, Overbeck, T., additional, Thomas, M., additional, von Pawel, J., additional, Reck, M., additional, Schuette, W., additional, Hagen, V., additional, Schneider, C.-P., additional, Georgoulias, V., additional, Varthalitis, I., additional, Zarogoulidis, K., additional, Syrigos, K., additional, Papandreou, C., additional, Bocskei, C., additional, Csanky, E., additional, Juhasz, E., additional, Losonczy, G., additional, Mark, Z., additional, Molnar, I., additional, Papai-Szekely, Z., additional, Tehenes, S., additional, Vinkler, I., additional, Almel, S., additional, Bakshi, A., additional, Bondarde, S., additional, Maru, A., additional, Pathak, A., additional, Pedapenki, R.M., additional, Prasad, K., additional, Prasad, S.V.S.S., additional, Kilara, N., additional, Gorijavolu, D., additional, Deshmukh, C.D., additional, John, S., additional, Sharma, L.M., additional, Amoroso, D., additional, Bajetta, E., additional, Bidoli, P., additional, Bonetti, A., additional, De Marinis, F., additional, Maio, M., additional, Passalacqua, R., additional, Cascinu, S., additional, Bearz, A., additional, Bitina, M., additional, Brize, A., additional, Purkalne, G., additional, Skrodele, M., additional, Baba, A.A., additional, Ratnavelu, K., additional, Saw, M.H., additional, Samson-Fernando, M.C., additional, Ladrera, G.E., additional, Jassem, J., additional, Koralewski, P., additional, Serwatowski, P., additional, Krzakowski, M., additional, Cebotaru, C., additional, Filip, D., additional, Ganea-Motan, D.E., additional, Ianuli, C.H., additional, Manolescu, I.G., additional, Udrea, A., additional, Burdaeva, O., additional, Byakhov, M., additional, Filippov, A., additional, Lazarev, S., additional, Mosin, I., additional, Orlov, S., additional, Udovitsa, D., additional, Khorinko, A., additional, Protsenko, S., additional, Lim, H.L., additional, Tan, Y.O., additional, Tan, E.H., additional, Bastus Piulats, R., additional, Garcia-Foncillas, J., additional, Valdivia, J., additional, de Castro, J., additional, Domine Gomez, M., additional, Kim, S.W., additional, Lee, J.-S., additional, Kim, H.K., additional, Lee, J.S., additional, Shin, S.W., additional, Kim, D.-W., additional, Kim, Y.-C., additional, Park, K.C., additional, Chang, C.-S., additional, Chang, G.-C., additional, Goan, Y.-G., additional, Su, W.-C., additional, Tsai, C.-M., additional, Kuo, H.-P., additional, Benekli, M., additional, Demir, G., additional, Gokmen, E., additional, Sevinc, A., additional, Haigentz, M., additional, Agarwal, M., additional, Pandit, S., additional, Araujo, R., additional, Vrindavanam, N., additional, Bonomi, P., additional, Berg, A., additional, Wade, J., additional, Bloom, R., additional, Amin, B., additional, Camidge, R., additional, Hill, D., additional, Rarick, M., additional, Flynn, P., additional, Klein, L., additional, Lo Russo, K., additional, Neubauer, M., additional, Richards, P., additional, Ruxer, R., additional, Savin, M., additional, Weckstein, D., additional, Rosenberg, R., additional, Whittaker, T., additional, Richards, D., additional, Berry, W., additional, Ottensmeier, C., additional, Dangoor, A., additional, Steele, N., additional, Summers, Y., additional, Rankin, E., additional, Rowley, K., additional, Giridharan, S., additional, Kristeleit, H., additional, Humber, C., additional, and Taylor, P., additional

Published
2013
Full Text
View/download PDF

44. Randomised controlled trial on the effectiveness of home-based walking exercise on anxiety, depression and cancer-related symptoms in patients with lung cancer.

Author

Chen, H-M, Tsai, C-M, Wu, Y-C, Lin, K-C, and Lin, C-C

Subjects
*LUNG cancer patients, *WALKING, *ALTERNATIVE treatment for anxiety, *EXERCISE physiology, *RANDOMIZED controlled trials, ALTERNATIVE treatment for mental depression
Abstract

Background:Although exercise has been addressed as an adjuvant treatment for anxiety, depression and cancer-related symptoms, limited studies have evaluated the effectiveness of exercise in patients with lung cancer.Methods:We recruited 116 patients from a medical centre in northern Taiwan, and randomly assigned them to either a walking-exercise group (n=58) or a usual-care group (n=58). We conducted a 12-week exercise programme that comprised home-based, moderate-intensity walking for 40 min per day, 3 days per week, and weekly exercise counselling. The outcome measures included the Hospital Anxiety and Depression Scale and the Taiwanese version of the MD Anderson Symptom Inventory.Results:We analysed the effects of the exercise programme on anxiety, depression and cancer-related symptoms by using a generalised estimating equation method. The exercise group patients exhibited significant improvements in their anxiety levels over time (P=0.009 and 0.006 in the third and sixth months, respectively) and depression (P=0.00006 and 0.004 in the third and sixth months, respectively) than did the usual-care group patients.Conclusions:The home-based walking exercise programme is a feasible and effective intervention method for managing anxiety and depression in lung cancer survivors and can be considered as an essential component of lung cancer rehabilitation. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

46. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer

Author

Yang, C H, primary, Tsai, C M, additional, Wang, L S, additional, Lee, Y C, additional, Chang, C J, additional, Lui, L T, additional, Yen, S H, additional, Hsu, C, additional, Cheng, A L, additional, Liu, M Y, additional, Chiang, S C, additional, Chen, Y M, additional, Luh, K T, additional, Huang, M H, additional, Yang, P-C, additional, and Perng, R-P, additional

Published
2002
Full Text
View/download PDF

50. Submesoscale Structure of the California Current Near San Clements Island

Author

NAVAL POSTGRADUATE SCHOOL MONTEREY CA, Tsai, C. M., Jessen, Paul F., Chu, P. C., Collins, Curtis A., NAVAL POSTGRADUATE SCHOOL MONTEREY CA, Tsai, C. M., Jessen, Paul F., Chu, P. C., and Collins, Curtis A.

Abstract

The purpose of the San Clemente Basin Experiment (SCBE) was to survey the upper ocean currents and temperature in a region southwest of San Clemente Island (SCI). To accomplish this, two cruises were made during which currents were measured by using a shipboard mounted Acoustic Doppler Current Profile (ADCP). Temperature was measured during the second cruise by deploying expendable bathythermographs. The first cruise took place during 17-21 July 1989 and the second one during 2-6 September 1989. Data indicate a variety of features. Two different flow patterns were observed: Strong poleward alongshore flow (about 40 cm/s) occurred 40-60 km west of SCI and small scale eddies were seen further offshore, i.e. farther than 60 km west of SCI. The alongshore flow intensified poleward, reaching 300 m depth. The smaller scale eddies have a length scale of about 10 km and are believed to be associated with larger scale horizontal shear due to the California Current. Keywords: Coastal circulation; Upper ocean currents; Nearshore eddies.

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results